Literature DB >> 10543876

Crystal structure of human DT-diaphorase: a model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954).

J V Skelly1, M R Sanderson, D A Suter, U Baumann, M A Read, D S Gregory, M Bennett, S M Hobbs, S Neidle.   

Abstract

The crystal structure of human DT-diaphorase (NAD(P)H oxidoreductase (quinone); EC 1.6.99.2) has been determined to 2.3 A resolution. There are only minor differences in shape and volume between the active sites of the rat and human enzymes and in the hydrophobic environment in the vicinity of the substrate. The isoalloxazine ring of the bound FAD is more buried in the human structure. Molecular modeling was used to examine optimal positions for the antitumor prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide) in both the human and rat enzyme active sites. This suggests that the position of CB1954 in the active site of the human enzyme is very similar to that in the rat, although there are detailed differences in the predicted patterns of hydrogen bonding between side chains and the drug. Some of the differences are a consequence of the shift in position for the FAD molecule and may contribute to the observed differences in rate of the two-electron reduction of CB1954.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543876     DOI: 10.1021/jm991060m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Functional Annotation of a Presumed Nitronate Monoxygenase Reveals a New Class of NADH:Quinone Reductases.

Authors:  Jacob Ball; Francesca Salvi; Giovanni Gadda
Journal:  J Biol Chem       Date:  2016-08-08       Impact factor: 5.157

2.  KefF, the regulatory subunit of the potassium efflux system KefC, shows quinone oxidoreductase activity.

Authors:  Lisbeth Lyngberg; Jessica Healy; Wendy Bartlett; Samantha Miller; Stuart J Conway; Ian R Booth; Tim Rasmussen
Journal:  J Bacteriol       Date:  2011-07-08       Impact factor: 3.490

3.  Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.

Authors:  Maria F Mendoza; Nicole M Hollabaugh; Suraj U Hettiarachchi; Robin L McCarley
Journal:  Biochemistry       Date:  2012-09-28       Impact factor: 3.162

4.  Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity.

Authors:  Clare F Megarity; David J Timson
Journal:  Biosci Rep       Date:  2019-09-06       Impact factor: 3.840

5.  Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release.

Authors:  M Faig; M A Bianchet; P Talalay; S Chen; S Winski; D Ross; L M Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

6.  Identification of NAD(P)H quinone oxidoreductase activity in azoreductases from P. aeruginosa: azoreductases and NAD(P)H quinone oxidoreductases belong to the same FMN-dependent superfamily of enzymes.

Authors:  Ali Ryan; Elise Kaplan; Jean-Christophe Nebel; Elena Polycarpou; Vincenzo Crescente; Edward Lowe; Gail M Preston; Edith Sim
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

Review 7.  Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch.

Authors:  David Ross; David Siegel
Journal:  Front Physiol       Date:  2017-08-24       Impact factor: 4.566

Review 8.  Roles of NAD(P)H:quinone Oxidoreductase 1 in Diverse Diseases.

Authors:  Wang-Soo Lee; Woojin Ham; Jaetaek Kim
Journal:  Life (Basel)       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.